David M. Epstein, PhD is founder & CEO of Black Diamond Therapeutics. David is a biopharma leader and executive who has successfully led large and small R&D teams in academic, virtual, start-up, mid-size and global large-pharma settings. His teams have progressed multiple novel agents through development in oncology, cardiovascular disease, and retinal degeneration. David was Chief Scientific Officer at Astellas/OSI Pharmaceuticals, and previously a founder of Archemix Corp.Most recently Vice Dean, Innovation & Entrepreneurship, and Associate Professor in Cancer & Stem Cell Biology at Duke-NUS Medical School, Singapore, David founded and built Duke-NUS’s Centre for Technology & Development (CTeD). The Centre has developed a pipeline of innovation projects, completing 2 product-development biopharma partnerships, and 7 spin-outs from its technologies.David’s research focuses on RNA splicing and immune-tumor cell interactions in cancer. He earned a Ph.D. in Biochemistry at Brandeis University and completed a joint post-doctoral fellowship leading a collaboration in protein structure, function and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
Black Diamond Therapeutics | Founder, President & Chief Executive Officer | — | — | Detail |